Australian prostate cancer technology company Minomic has appointed a Clinical Advisory Panel to assist in the commercialisation of its MiCheck prostate cancer screening technology.
Six medical experts have formed a Clinical Advisory Panel, effective immediately.
The panel is Chaired by Professor David Gillatt, who is internationally regarded as a prostate and bladder cancer surgeon, as well as advising health care, medical device and global pharmaceutical companies.
Other appointees include Dr Neal Shore, Associate Professor Declan Murphy, Professor Mark Emberton, Professor Daniel Chan and Professor John Babich.
The company's MiCheck test as a novel prostate cancer screening technology is on track for commercial launch in early 2016.
Minomic Chief Executive Officer Dr Brad Walsh said the appointment of the Clinical Advisory Panel reflected the opportunity afforded by the MiCheck technology.
“That we have been able to assemble a clinical team of such a high calibre is further validation of the high level science underpinning our endeavour,” he said.
He continued, “We are confident this is the right clinical team to steer us through the next critical months of development as we prepare to launch the MiCheck technology into the global marketplace.
“We have ensured the team we have assembled has extensive international outreach, with our appointments spanning the United States, the UK and Australia. All are critical marketing regions for the MiCheck technology. Not only does our team now have the appropriate clinical experience, they also bring a thorough insight into these high value sales markets.”
Professor David Gillatt said he was pleased to be appointed Chair of the panel. "I feel that as a group we will be able to assist Minomic progress the introduction of its important technology.”